Francesco Di Costanzo

Author

Azienda Ospedaliero-Universitaria Careggi ORCID

Also Known As

A. Rizzi, Costanzo, Francesco, F Buzzi, F COSTANZO, F Costanzo, F Di Costanzo, F. Costanzo, F. Di Costanzo, F. Ferraù, F.D. Costanzo

339

Publications

8.9K

Citations

H-Index

Concepts

All Affiliations

Azienda Ospedaliero-Universitaria Careggi Istituti di Ricovero e Cura a Carattere Scientifico Fondazione IRCCS Istituto Nazionale dei Tumori University of Florence Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori

About

Francesco Di Costanzo is an author at Azienda Ospedaliero-Universitaria Careggi specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	32	59	4.3K
2	Health Sciences	10	10	631
3	Public Health	3	3	117
4	Education	1	1	35
5	Nursing	1	1	61

Francesco Di Costanzo

111

Publications

7.8K

Citations

H-Index

Page 1

	Year	Citations
Phase III Randomized Trial Comparing Three Platinum-Based Doublets in Advanced Non–Small-Cell Lung Cancer Giorgio V. Scagliotti, Filippo de Marinis, Monica Rinaldi, Journal of Clinical Oncology	2002	890
Randomized Phase III Trial Comparing Biweekly Infusional Fluorouracil/Leucovorin Alone or With Irinotecan in the Adjuvant Treatment of Stage III Colon Cancer: PETACC-3 Eric Van Cutsem, Roberto Labianca, G. Bodoky, Journal of Clinical Oncology Surgical OncologyGastrointestinal OncologyMedicineCancer ManagementPharmacology	2009	466
Clinical determinants of survival in patients with 5-fluorouracil- based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients C.-H. Köhne, David Cunningham, Francesco Di Costanzo, Annals of Oncology Clinical DeterminantsSurgical OncologyMultivariate AnalysisMedicineColorectal Cancer	2002	456
Gemcitabine and Cisplatin Versus Mitomycin, Ifosfamide, and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Randomized Phase III Study of the Italian Lung Cancer Project Lucio Crinò, Giorgio V. Scagliotti, Serafino Ricci, Journal of Clinical Oncology	1999	366
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial Chiara Cremolini, Carlotta Antoniotti, Daniele Rossini, The Lancet Oncology OncologyMedicineColorectal CancerPathologyUpfront Folfoxiri	2020	309
Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Single-Agent Gemcitabine As First-Line Treatment of Patients With Advanced Pancreatic Cancer: The GIP-1 Study Giuseppe Colucci, Roberto Labianca, Francesco Di Costanzo, Journal of Clinical Oncology	2010	301
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial Charles S. Fuchs, Kohei Shitara, Maria Di Bartolomeo, The Lancet Oncology First-line TherapyGastrointestinal OncologyMedicinePathologyMetastatic Gastric	2019	276
Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials Gunnar Folprecht, David Cunningham, Paul J. Ross, Annals of Oncology 5-Fluorouracil-based ChemotherapyElderly PatientsGastrointestinal OncologyMedicinePharmacology	2004	256
Front‐line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma Vittorio Franciosi, Giorgio Cocconi, Maria Michiara, Cancer Neuro-oncologySurgical OncologyBrain MetastasesRadiation TherapyMedicine	1999	239
CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis Masatoshi Kudo, Ana Matilla, Armando Santoro, Journal of Hepatology	2021	215

Page 1